Ordering Pyrilutamide from Minoxidilmax to use as an experimental topical treatment for hair loss, with discussion of the carrier used in trials and encouragement from other users.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
Kopexil (Aminexil) is not approved as a drug in the US and Europe because it is marketed as a cosmetic, which requires less testing and regulation. L'Oreal's 1.5% Aminexil is noted to reduce hair shedding, but its efficacy as a drug is not proven.
The user is pausing finasteride for blood donation and is concerned about its effect on DHT levels. They plan to supplement with saw palmetto and pumpkin seed oil during the pause.
The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.
Hair loss discussion focuses on adding an anti-androgen to stack with topical finasteride. Eucapil (fluridil) is suggested for its safety and minimal side effects.
The conversation is about finding sources for topical anti-androgens like CB, pyrilutamide, fluridil, and aflatridol for hair loss treatment. The user is considering using CB powder from IndiaMart but is concerned about side effects from finasteride and minoxidil.
The conversation discusses the lack of experiments combining verteporfin and microneedling for hair loss treatment. The user expresses interest in participating in a group buy to try this method.
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.